Trial Profile
A prospective multicentric study evaluating long term treatment with Secukinumab in patients with moderate to severe psoriasis in clinical practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2018
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Therapeutic Use
- 10 May 2018 New trial record